Adults recently diagnosed with immunoglobulin A nephropathy who were assigned sparsentan as first-line therapy experienced rapid and sustained reductions in proteinuria, according to ...

BOSTON -- Patients with focal segmental glomerulosclerosis (FSGS) achieved some degree of proteinuria remission more often ...

One advantage of sparsentan over other medications for IgA nephropathy is that it does not suppress your immune system, lowering your risk for infections. Iptacopan acts on a specific process in ...

Travere Therapeutics and partner CSL Vifor could be weeks away from EU approval of sparsentan for IgA nephropathy, after getting a positive opinion on the drug from the EMA’s human medicines ...

A post-hoc analysis of the DUPLEX trial shows significantly greater improvements in proteinuria-related outcomes vs irbesartan for tough-to-treat FSGS.

Multiple medications are now available to treat IgA nephropathy, including budesonide (Tarpeyo), sparsentan (Filspari), and iptacopan (Fabhalta). But Miller’s treatment options were more limited ...

The FDA granted accelerated approval to atrasentan (Vanrafia) for the reduction of proteinuria in adults with primary immunoglobulin A (IgA) nephropathy, maker Novartis announced late on Wednesday.

The late-breaking oral presentation will feature new analyses from the Phase 3 DUPLEX Study of FILSPARI® (sparsentan ... as a foundational therapy in IgA nephropathy (IgAN).

Vanrafia (atrasentan) is the first drug in the selective endothelin A receptor antagonist (ERA) class to be cleared in the US for IgAN, a disease characterised by the accumulation of antibodies in the ...

IgA nephropathy (IgAN), also called Berger's ... Concomitant use with a strong CYP3A inhibitor increases sparsentan exposure which may increase the risk of FILSPARI adverse reactions.